Clinical trials: Overweight, Obesity
Osteoarthritis, Overweight or Obesity
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have…
- Trial name
- ENLIGHTEN-4 (NCT07353931)
- Testing
- Eloralintide
- Where
- 153 sites in United States, Argentina and 12 more
- Volunteers
- 900 people
- Sponsor
- Eli Lilly and Company
Cholesterol Lowering
Influence of Polyglucosamine L112 on Serum Surrogate Markers of Cholesterol Absorption
Obesity is widespread and the number of overweight people has tripled from 1975 to 2016. According to the WHO (World Health Organisation), 1.9 billion adults worldwide are overweight, of which 650 million are obese.
- Trial name
- NCT05038436
- Testing
- Polyglucosamine L112
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Certmedica International GmbH
Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
This is a Phase I, open-label, two-cohort study designed to evaluate the drug-drug interaction potential of multiple-dose UBT251 Injection in adult participants with overweight or obesity.
- Trial name
- NCT07785934
- Testing
- UBT251, Metformin hydrochloride, Warfarin Sodium
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Obesity &Amp; Overweight, Chronic Kidney Disease
UBT251 Injection Phase II Clinical Study (CKD)
This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population
- Trial name
- NCT07134335
- Testing
- UBT251
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Overweight
Efficacy Study for SD Device
The purpose of this study is to determine whether the SD unique device is effective in treatment of overweight and obesity.
- Trial name
- NCT01534325
- Testing
- SD, Control
- Where
- 2 sites in Israel
- Volunteers
- 150 people
- Sponsor
- Beck Medical Ltd.
Metabolism and Nutrition Disorder, Overweight or Obesity
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants…
- Trial name
- STEP 1 (NCT03548935)
- Testing
- Semaglutide
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 1,961 people
- Sponsor
- Novo Nordisk A/S
Morbid Obesity
Six-month Study to Compare the Effects of Volume- and Pressure-Guided Adjustments on Weight Loss and Satiety
The purpose of this protocol is to determine how band fill volumes that are based on intraband pressure readings can influence the comfortability of the band and to compare weight loss with this methodology to weight loss with…
- Trial name
- NCT00960843
- Testing
- Intraband pressure recording system, Conventional Adjustment
- Where
- 2 sites in Australia, Czechia
- Volunteers
- 51 people
- Sponsor
- Ethicon Endo-Surgery
Obesity, Overweight
A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses
This study is a randomized, double-blind, placebo-controlled, dose-escalation phase I clinical trial. This study consists of two parts: the single-dose escalation study (SAD) in healthy subjects and the multiple-dose escalation…
- Trial name
- NCT07280936
- Testing
- SHR-2906 Injection
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Obesity
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.
- Trial name
- NCT07639021
- Testing
- NNC0662-0419, Semaglutide
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 233 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
- Trial name
- NCT02453711
- Testing
- semaglutide, liraglutide
- Where
- 74 sites in United States, Australia and 6 more
- Volunteers
- 957 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or Obesity
This study is being done to learn how the study medicine affects the body. It will also assess how safe it is for people who take it. The researchers will use blood tests to measure how much medicine is in the blood.
- Conditions
- Overweight, Obesity, Healthy
- Trial name
- NCT07725809
- Testing
- PF-08653945
- Where
- Belgium
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
A Study to Understand the Distribution of Obesity Classes and Obesity Related Diseases in People With Obesity Across Countries in Czech Republic, Hungary and Poland
The study is intended to understand the distribution of different obesity classes and obesity related diseases (diseases that present along with obesity) in patients with body mass index (BMI) ≥ 30 kg/m^2.
- Trial name
- ExplorEUEast (NCT05795166)
- Testing
- No treatment given
- Volunteers
- 1,241 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to Investigate the Effect of Food on the Pharmacokinetics of HSG4112
1. Study Objective: The objective of this clinical trial is to investigate the effect of food on the pharmacokinetics of HSG4112 after oral administration in healthy male subjects. 2.
- Trial name
- NCT04733001
- Testing
- HSG4112
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Glaceum
Obesity
Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers
The purpose of this study is to determine whether CP-866,087 is effective in the weight loss of overweight patients.
- Trial name
- NCT00479492
- Testing
- CP-866,087
- Where
- 4 sites in United States
- Volunteers
- 94 people
- Sponsor
- Pfizer
Sleep Apnea
A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults
The primary objectives of this study are to evaluate the safety and efficacy of VI-0521 compared to placebo in the treatment of obese adults with obstructive sleep apnea (OSA) and to assess the relative contributions of weight…
- Trial name
- NCT00745251
- Testing
- VI-0521
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- VIVUS LLC
Healthy Volunteers
A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects
PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after 2 weeks of dosing of PF-06427878 in…
- Trial name
- NCT02855177
- Testing
- PF-06427878
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Metabolic Syndrome, Obesity
Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers
The purpose of this study is to investigate the safety and tolerability of MB12066 after a single or multiple oral dose and to investigate the pharmacokinetic characteristics of MB12066 after a single or multiple oral dose.
- Trial name
- NCT01444677
- Testing
- MB12066
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Yungjin Pharm. Co., Ltd.
Overweight , Obesity
Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07778693
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 760 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Type 2 Diabetes, Metabolic Syndrome
Clinical Study on the Effect of a Synbiotic on Body Fat Mass
In this trial the effect of a synbiotic consisting of the three different strains of Lactobacillus fermentum and acacia gum (gum arabic) on body fat mass, body weight, long-term glycemia, insulin resistance and other risk factors…
- Conditions
- Type 2 Diabetes, Metabolic Syndrome, Obesity, Abdominal, Obesity, Visceral
- Trial name
- NCT04754464
- Testing
- synbiotic, microcrystalline cellulose
- Where
- 2 sites in Austria, Germany
- Volunteers
- 120 people
- Sponsor
- Slimbiotics GmbH
Infant Formula, Growth
Lower Protein Intake and Long-term Risk of Obesity and Cardiovascular Disease
The primary objective of this study is to investigate if consumption of lower protein formula can slow the rate of weight gain of formula-fed infants between 3 and 12 months of age.
- Trial name
- BabyGrowth (NCT03456934)
- Testing
- Modified infant formula, Standard infant formula
- Where
- United Kingdom
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.